AARD
Aardvark Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
None
9 analysts
$7.60
+$2.60 (+52.00%)
Target:
$15.44
(103.2%)
Sign in to add AARD to a watchlist or set price alerts.
Price History
Fundamentals
| Market Cap | $121.52M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.72 |
| EPS (TTM) | $-3.21 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $15.44 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 83.6 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | 260.7K |
| Volume | $4.09M |
Performance Analysis
NEUTRALAARD presents a mixed picture with both positive and negative indicators.
-
RSI at 83.6 indicates overbought conditions — a pullback may be due.
~
Wall Street consensus is "none" from 9 analysts.
+
Average analyst target of $15.44 implies 103.2% upside.
Recent News
Loading news...
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report